XBiotech Inc.
NASDAQ:XBITBiotechnology
-$0.02 today
- Market cap
- $51.22M
- Beta
- 0.84
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.32
Volume 0.05M
Average 0.03M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
XBiotech Inc.
NASDAQ:XBIT
Intrinsic Alpha fair value
Locked
Current Price
$1.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A — |
| Revenue | N/A | N/A | N/A | N/A — |
| Net Income | N/A | N/A | N/A | N/A — |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Relmada Therapeutics, Inc. NASDAQ:RLMD | $449.08M | $4.21 | Not rated | -9.6 | -28.01% |
Nutriband Inc. NASDAQ:NTRB | $74.15M | $6.10 | Not rated | -1.8 | -0.79% |
Adagene Inc. NASDAQ:ADAG | $64.38M | $1.71 | Not rated | -7.9 | +13.56% |
Fortress Biotech, Inc. NASDAQ:FBIO | $62.70M | $1.88 | Undervalued | 0.7 | -30.04% |
Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV | $62.14M | $1.45 | Not rated | -0.8 | -38.05% |
Gain Therapeutics, Inc. NASDAQ:GANX | $44.36M | $1.04 | Not rated | -3.6 | -58.60% |
Adicet Bio, Inc. NASDAQ:ACET | $26.03M | $2.78 | Overvalued | -0.8 | -40.15% |
TScan Therapeutics, Inc. NASDAQ:TCRX | $10.20M | $0.16 | Not rated | -1.0 | -16.29% |
Continue the stock analysis
Jump to another research area for this company.